G
Gianpaolo Marcacci
Publications - 22
Citations - 398
Gianpaolo Marcacci is an academic researcher. The author has contributed to research in topics: Transplantation & Internal medicine. The author has an hindex of 9, co-authored 17 publications receiving 346 citations.
Papers
More filters
Journal ArticleDOI
Rituximab therapy for chronic lymphocytic leukemia‐associated autoimmune hemolytic anemia
Giovanni D'Arena,Luca Laurenti,Silvana Capalbo,Alfonso Maria D'Arco,Rosaria De Filippi,Gianpaolo Marcacci,Nicola Di Renzo,Sergio Storti,Catello Califano,Maria Luigia Vigliotti,Michela Tarnani,Felicetto Ferrara,Antonio Pinto +12 more
TL;DR: The results prove that the anti‐CD20 monoclonal antibody rituximab is an effective and well‐tolerated alternative treatment for CLL‐associated AIHA.
Journal ArticleDOI
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
Gaetano Corazzelli,Gaetana Capobianco,Manuela Arcamone,Pier Ferruccio Ballerini,Emilio Iannitto,Filippo Russo,Ferdinando Frigeri,Cristina Becchimanzi,Gianpaolo Marcacci,Annarosaria De Chiara,Antonio Pinto +10 more
TL;DR: Both regimes showed good tolerability and appealing response rates, but patients continuously relapsed without a clear plateau on survival curves.
Journal ArticleDOI
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
Gaetano Corazzelli,Ferdinando Frigeri,Manuela Arcamone,Anna Lucania,Maria RosariaVilla,Emanuela Morelli,Alfonso Amore,Gaetana Capobianco,Antonietta Caronna,Cristina Becchimanzi,Francesco Volzone,Gianpaolo Marcacci,Filippo Russo,Rosaria De Filippi,Lucia Mastrullo,Antonio Pinto +15 more
TL;DR: R‐COMP‐14 is feasible and ensures a substantial DFS to poor‐risk DLBCL patients who would have been denied anthracycline‐based treatment due to cardiac morbidity and the Age‐adjusted Charlson Comorbidity Index predicted both treatment discontinuation rate and TTF.
Journal ArticleDOI
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study
Maurizio Musso,Renato Scalone,Gianpaolo Marcacci,Francesco Lanza,N. Di Renzo,Nicola Cascavilla,P. Di Bartolomeo,Alessandra Crescimanno,Tania Perrone,Antonello Pinto +9 more
TL;DR: Although toxicity and engraftment times compared favorably with BEAM, longer follow-up is needed to evaluate fully its efficacy and long-term safety.
Journal ArticleDOI
Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma.
Gaetano Corazzelli,Rosaria De Filippi,Gaetana Capobianco,Ferdinando Frigeri,Vincenzo De Rosa,Giancarla Iaccarino,Filippo Russo,Manuela Arcamone,Cristina Becchimanzi,Stefania Crisci,Gianpaolo Marcacci,Barbara Amoroso,Secondo Lastoria,Antonio Pinto +13 more
TL;DR: Flares mimicked tumor progression but were effectively managed with anti-inflammatory treatment and followed by a clinical response, suggesting that they may mirror the pleiotropic actions of lenalidomide on HL microenvironment.